Tsoi M S, Storb R, Weiden P L, Thomas E D
J Immunol. 1977 May;118(5):1799-805.
Fifteen patients with aplastic anemia and 13 with acute leukemia were studied 36 to 1547 days after treatment with high-dose cyclophosphamide and/or total-body irradiation and marrow transplantation from HLA identical siblings. Peripheral blood lymphocytes from patients and normals (marrow donors and healthy unrelated individuals) were tested for cell inhibition (CI) of cultured skin fibroblasts from both patients and donors by using the microcytotoxicity assay. In addition, blocking of CI by factors in patient serum was studied. Three groups of patients were studied. Patients in group I were stable long-term survivors without evidence of graft-vs-host diseases (GVHD) between 250 to 1547 days postgrafting. Patients in group II were short-term survivors with or without acute GVHD between 36 and 144 days postgrafting. Patients in group III had chronic GVHD either at the time of testing or developed chronic GVHD subsequent to CI testing between days 61 and 960 postgrafting. Eleven of 14 patients in group I showed absence of both CI and serum blocking and three showed CI and blocking. Patients in group II without acute GVHD showed absence of CI and serum blocking on three occasions, presence of CI and blocking on four occasions, and CI without blocking on three occasions. Patients in group II with acute GVHD showed absence of CI on one occasion and presence of CI and blocking on three occasions. Patients in group III showed absence of CI and blocking on seven occasions and CI without blocking on two occasions. These results suggest that the maintenance of stable graft-host tolerance in long-term survivors after marrow grafting from HLA identical donors does not depend on the presence of serum-blocking factors. Short-term survivors with and without GVHD showed a spectrum of in vitro reactivity with 50% of the patients showing serum-blocking factors, and these results did not appear to be correlated with presence or absence of acute GVHD. Finally, results of the microcytotoxicity assays failed to provide insight into the mechanism of chronic GVHD.
对15例再生障碍性贫血患者和13例急性白血病患者进行了研究,这些患者在接受大剂量环磷酰胺和/或全身照射以及来自 HLA 相同同胞的骨髓移植治疗后36至1547天。通过微量细胞毒性试验,检测了患者和正常人(骨髓供者和健康无关个体)外周血淋巴细胞对患者和供者培养皮肤成纤维细胞的细胞抑制(CI)作用。此外,还研究了患者血清中因子对CI的阻断作用。研究了三组患者。第一组患者是长期稳定存活者,在移植后250至1547天无移植物抗宿主病(GVHD)证据。第二组患者是短期存活者,在移植后36至144天有或无急性GVHD。第三组患者在检测时患有慢性GVHD,或在移植后61至960天的CI检测后发生慢性GVHD。第一组14例患者中有11例既无CI也无血清阻断,3例有CI和阻断。第二组无急性GVHD的患者有3次既无CI也无血清阻断,4次有CI和阻断,3次有CI但无阻断。第二组有急性GVHD的患者有1次无CI,3次有CI和阻断。第三组患者有7次既无CI也无阻断,2次有CI但无阻断。这些结果表明,来自 HLA 相同供者的骨髓移植后长期存活者稳定的移植物-宿主耐受性的维持并不依赖于血清阻断因子的存在。有和无GVHD的短期存活者表现出一系列体外反应性,50%的患者有血清阻断因子,这些结果似乎与急性GVHD的有无无关。最后,微量细胞毒性试验的结果未能深入了解慢性GVHD的机制。